EUVIMEDEUVIMED entdecken
EditorialOpen Access · CC BY 4.0

Editorial: AI-powered insights: predicting treatment response and prognosis in breast cancer

Tamer Ahmed Farrag, Ashraf Elbatanony, Mona Zaky, Khaled Abdelwahab, Yazan Masannat, Mohamed Shehata, Mostafa A Elhosseini

Frontiers in Oncology · 29.10.2026 · 16

DOI: 10.3389/fonc.2026.1996821 ↗

Kurz gefasst

Editorial in der Zeitschrift Frontiers in Oncology, online erschienen am 29.10.2026. Verfasst von Tamer Ahmed Farrag und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Electrical Engineering, College of Engineering, Taif University, Taif, Saudi Arabia. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast cancer remains a leading cause of cancer-related mortality among women worldwide, necessitating continuous refinement of clinical management strategies. Historically, diagnostic paradigms have relied heavily on traditional imaging modalities, such as mammography, ultrasound, and magnetic resonance imaging (MRI), which are often constrained by subjective interpretation, inter-observer variability, and reduced sensitivity in dense breast tissue. These limitations have driven a profound technological shift toward artificial intelligence (AI) and radiomics, enabling the high-throughput extraction of quantitative imaging features to noninvasively capture complex tumor heterogeneity. Crucially, this evolution has expanded beyond macroscopic radiological imaging into the frontier of AI-augmented pathology, or pathomics. By embracing multi-dimensional data integration-fusing radiomics, pathomics, and multi-omics-the field is achieving unprecedented precision in clinical oncology, shifting away from generalized guidelines toward individualized, dynamics-aware predictive modelling.The current landscape of breast cancer research leverages a broad spectrum of AI architectures to process diverse data modalities. For classical machine learning tasks handling tabular clinical data or extracted radiomic features, ensemble algorithms such as Random Forest (RF), Support Vector Machines (SVM), XGBoost, LightGBM, and CatBoost are predominantly utilized. Time-to-event prognosis frequently relies on specialized survival models, including the Accelerated Oblique Random Survival Forest (AORSF) (Wang et al., 2025b). Feature selection is rigorously managed via the Least Absolute Shrinkage and Selection Operator (LASSO) to minimize multicollinearity in high-dimensional datasets.In the realm of deep learning, convolutional neural networks (CNNs), such as ResNet50, DenseNet, and specialized variants (ULNet, PLNet) drive transfer learning and automated image classification tasks (Cossio et al., 2025;Peng et al., 2025) . Furthermore, advanced architectures-such as the Vision Transformer (ViT), the Unified Network for Image (UNI), the attentive tabular framework TabNet, and dynamics-aware sequence learners like ResponseNet-are increasingly deployed to capture global interactions and temporal patient treatment trajectories (Wang et al., 2025c;Wang et al., 2025d;Yue et al., 2026). To establish a comprehensive macro-level overview of these algorithmic paradigms, task-aware bibliometric mapping across 608 peer-reviewed publications (2020-2026) confirms a decisive architectural shift from classical convolutional neural network (CNN) backbones toward Vision Transformers (ViTs) and hybrid attention mechanisms (Mohamed et al., 2026). This quantitative synthesis demonstrates that while deep learning models increasingly dominate computational oncology, escalating model complexity underscores an urgent imperative for standardized hyperparameter tuning and transparent architectural reporting (Mohamed et al., 2026).The distribution of primary data modalities across the synthesized cohort is detailed in the The integration of the aforementioned modalities delineates four core clinical sub-themes driving personalized oncology: (Wang et al., 2025b).Prognostic models are essential for mapping the likelihood of locoregional recurrence and metastasis. Multimodal deep learning architectures that fuse preoperative ultrasound and core-needle biopsy images offer superior prediction of axillary lymph node metastasis compared to single-modality approaches (Peng et al., 2025). Concurrently, AI-augmented pathology employing transfer learning on whole-slide images automates sentinel lymph node analysis with clinical-grade accuracy, demonstrating high resilience to interhospital domain shifts (Cossio et al., 2025). For patients with TNBC, AI-driven ultrasound radiomics provides a powerful tool to predict postoperative locoregional recurrence and distinct patterns of distant metastasis (Zilalan et al., 2026). Machine learning algorithms concurrently identify high-risk prognostic survival metrics for severe conditions such as breast cancer liver metastases (Chen et al., 2025) and utilize XGBoost models to predict the co-occurrence of primary thyroid cancer (Yin et al., 2026). From an epidemiological and molecular standpoint, statistical modeling maps the rising global burden of elderly male breast cancer (Liu et al., 2026), while integrated transcriptomics identifies oncogenic drivers like CDK1 promoting progression through AKT activation (Zeng et al., 2025).The successful clinical translation of AI necessitates deep integration with humanistic, patientcentered care models. A comprehensive nursing-centered analytical framework asserts that while AI optimally handles data-heavy triage, decision support, and monitoring tasks, nurses must safeguard professional autonomy, preserve empathetic therapeutic relationships, and manage ethical governance across the personalized care continuum (Zhang et al., 2026). In addressing holistic symptom management, a rigorous meta-analysis confirms that mindfulness-based stress reduction (MBSR) significantly mitigates cancer-related fatigue, improving patients' overall quality of life and sleep continuity during therapy (Wang et al., 2025a).The continuous evolution of computational oncology has accelerated the development of generative AI applications and dynamic decision-making frameworks for sequence exploration in drug design. However, the translation of AI into routine clinical workflows faces substantial challenges. Dataset generalizability is a primary concern; models trained on single-center, retrospective datasets frequently experience degraded performance when transitioning to diverse, real-world populations due to domain shifts. Critical methodological hurdles continue to impede the seamless translation of AI algorithms into routine clinical workflows. AlthoughExplainable AI (XAI) visualizers-such as Grad-CAM, SHAP, and LIME-are increasingly deployed to mitigate black-box opacity, hyperparameter optimization (HPO) remains insufficiently reported, with only 15-25% of studies explicitly documenting tuning protocols (Mohamed et al., 2026). Furthermore, while some transformer-based and hybrid architectures report near-perfect benchmark performance (98-100%), these metrics often stem from singlecenter retrospective cohorts prone to internal validation bias, reinforcing the necessity for prospective, multi-institutional external validation (Mohamed et al., 2026). To build clinical trust, the pervasive "black box" problem of algorithmic interpretability must be mitigated.Studies are actively addressing this by developing intuitive visual interfaces, high-contrast probability heatmaps, and SHapley Additive exPlanations (SHAP) to provide feature attributions, allowing pathologists and oncologists to interact transparently with the model's rationale. Ultimately, establishing the synergistic integration of AI into clinical environments relies on robust institutional governance, clearly defining the collaborative division of labor, override thresholds, and accountability between intelligent tools and human healthcare professionals.The integration of artificial intelligence, advanced radiomics, and multi-omics represents a transformative milestone in the pursuit of precision medicine for breast cancer. By migrating from static diagnostic criteria to dynamic, patient-specific predictive frameworks, computational oncology provides highly actionable insights into early disease classification, therapeutic response forecasting, and longitudinal prognostic risk assessment. As researchers proactively confront the challenges of algorithmic transparency, dataset generalizability, and clinical workflow integration, the synergistic collaboration between human clinical expertise and AI-augmented analytics is poised to establish a new gold standard in personalized, patient-centered oncological care.

Schlagwörter

Stichwörter der Autor:innen

artificial intelligencebreast cancercomputational oncologymachine learningmulti-omicspathomicsprecision medicineradiomics

Autor:innen und Institutionen

  • Department of Electrical Engineering, College of Engineering, Taif University, Taif, Saudi Arabia.
  • Department of Cariology, Faculty of Medicine, Al Azhar University, Cairo, Egypt.
  • Diagnostic Radiology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
  • Surgical Oncology Department, Mansoura Oncology Center, Mansoura University, Mansoura, Egypt.
  • Bloomfield Hospital, Mid and South Essex NHS Foundation Trust, Basildon, United Kingdom.
  • Computer Science Major, James C. Bowling School of Business, Midway University, Midway, KY, United States.

Zitieren

APA

Farrag, T. A., Elbatanony, A., Zaky, M., Abdelwahab, K., Masannat, Y., Shehata, M., & Elhosseini, M. A. (2026). Editorial: AI-powered insights: predicting treatment response and prognosis in breast cancer. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1996821

Vancouver

Farrag TA, Elbatanony A, Zaky M, Abdelwahab K, Masannat Y, Shehata M, et al. Editorial: AI-powered insights: predicting treatment response and prognosis in breast cancer. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1996821

BibTeX
@article{Farrag2026,
  author = {Farrag, Tamer Ahmed and Elbatanony, Ashraf and Zaky, Mona and Abdelwahab, Khaled and Masannat, Yazan and Shehata, Mohamed and Elhosseini, Mostafa A},
  title = {Editorial: AI-powered insights: predicting treatment response and prognosis in breast cancer},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1996821}
}
Kostenlos starten →